IGBA launches whitepaper on global generic and biosimilar medicines industry

It covers opportunities, challenges and disruptions for the industry, vision for 2030 as well as actions needed to achieve this vision.

The International Generic and Biosimilar Medicines Association (IGBA) is launching a whitepaper: A Vision for the Generic and Biosimilar Medicines Industry. It will cover the strong contribution of the pharma sector to global health outcomes and economies, the opportunities, challenges and disruptions for the industry, its 2030 vision as well as actions needed to achieve this vision.
“The generic and biosimilar medicines industry has played and continues to play a crucial role in the ongoing COVID-19 public health crisis and in the overall healthcare ecosystems” commented Sudarshan Jain, IGBA Chair. “The IGBA 2030 vision reflects our efforts to ensure that this industry can continue to contribute deeply to enhancing reach and access to high quality and cost-effective therapies globally. They are needed more than ever,” Jain added.

A statement informed, “The whitepaper is the result of extensive input from fourteen generic and biosimilar medicines companies and IGBA member associations, and supports the global recovery efforts to rethink, build and secure a future that addresses the inequalities in healthcare, while supporting sustainability.”

“To help industry achieve its 2030 vision, we need efficient, supportive and consistent regulatory frameworks, equitable patent and litigation systems fostering innovation while enabling access, open international borders and secure trade flows as well as encouragement for investment in new technology and innovation”, concluded Suzette Kox, IGBA Secretary General